X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SUN PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SUN PHARMA IPCA LABS/
SUN PHARMA
 
P/E (TTM) x 27.5 15.0 182.9% View Chart
P/BV x 2.1 3.5 59.7% View Chart
Dividend Yield % 0.2 0.2 112.4%  

Financials

 IPCA LABS   SUN PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-17
SUN PHARMA
Mar-16
IPCA LABS/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs6431,201 53.6%   
Low Rs503706 71.2%   
Sales per share (Unadj.) Rs254.4117.5 216.6%  
Earnings per share (Unadj.) Rs16.119.6 82.0%  
Cash flow per share (Unadj.) Rs29.823.8 125.1%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.20.1 166.4%  
Book value per share (Unadj.) Rs194.6130.5 149.1%  
Shares outstanding (eoy) m126.202,406.60 5.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.38.1 27.7%   
Avg P/E ratio x35.748.7 73.3%  
P/CF ratio (eoy) x19.240.1 48.0%  
Price / Book Value ratio x2.97.3 40.3%  
Dividend payout %6.25.1 121.9%   
Avg Mkt Cap Rs m72,3002,294,813 3.2%   
No. of employees `00013.314.7 90.2%   
Total wages/salary Rs m6,96047,971 14.5%   
Avg. sales/employee Rs Th2,413.519,169.8 12.6%   
Avg. wages/employee Rs Th523.23,253.0 16.1%   
Avg. net profit/employee Rs Th152.43,197.9 4.8%   
INCOME DATA
Net Sales Rs m32,106282,697 11.4%  
Other income Rs m2266,170 3.7%   
Total revenues Rs m32,332288,867 11.2%   
Gross profit Rs m4,44883,239 5.3%  
Depreciation Rs m1,73010,135 17.1%   
Interest Rs m2414,769 5.0%   
Profit before tax Rs m2,70374,505 3.6%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m0-6,852 0.0%   
Tax Rs m6759,349 7.2%   
Profit after tax Rs m2,02847,159 4.3%  
Gross profit margin %13.929.4 47.0%  
Effective tax rate %25.012.5 199.1%   
Net profit margin %6.316.7 37.9%  
BALANCE SHEET DATA
Current assets Rs m17,340308,646 5.6%   
Current liabilities Rs m9,559132,477 7.2%   
Net working cap to sales %24.262.3 38.9%  
Current ratio x1.82.3 77.9%  
Inventory Days Days10083 120.9%  
Debtors Days Days5788 64.8%  
Net fixed assets Rs m20,779133,606 15.6%   
Share capital Rs m2522,407 10.5%   
"Free" reserves Rs m24,499266,909 9.2%   
Net worth Rs m24,553314,042 7.8%   
Long term debt Rs m3,51731,167 11.3%   
Total assets Rs m39,595542,196 7.3%  
Interest coverage x12.216.6 73.5%   
Debt to equity ratio x0.10.1 144.3%  
Sales to assets ratio x0.80.5 155.5%   
Return on assets %5.79.6 59.8%  
Return on equity %8.315.0 55.0%  
Return on capital %10.517.8 59.1%  
Exports to sales %48.614.0 347.5%   
Imports to sales %14.23.1 453.1%   
Exports (fob) Rs m15,61739,572 39.5%   
Imports (cif) Rs m4,5718,882 51.5%   
Fx inflow Rs m15,61742,171 37.0%   
Fx outflow Rs m5,82821,583 27.0%   
Net fx Rs m9,79020,588 47.5%   
CASH FLOW
From Operations Rs m2,76467,694 4.1%  
From Investments Rs m-1,432-44,549 3.2%  
From Financial Activity Rs m-1,591-19,243 8.3%  
Net Cashflow Rs m-2593,902 -6.6%  

Share Holding

Indian Promoters % 45.9 63.7 72.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 5.1 222.2%  
FIIs % 25.3 23.0 110.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 8.3 209.6%  
Shareholders   36,892 133,026 27.7%  
Pledged promoter(s) holding % 2.1 0.5 403.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  FULFORD INDIA  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Aug 21, 2017 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - WOCKHARDT LTD. COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS